Top Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watchrttnews·Jul 20 at 10:01 PMARMP-10.73%ZYBT-3.89%
Armata Shares Surge on Progress Toward Late-Stage Trial of Superbug TreatmentMorningStar·Jul 20 at 10:29 AMARMP-10.73%
07:00 ETArmata Pharmaceuticals Achieves Key Progress Across Clinical, Regulatory and Manufacturing Activities Supporting Planned Phase 3 Initiation of AP-SA02prnewswire·Jul 20 at 06:01 AMARMP-10.73%
Armata Pharmaceuticals Receives Agreement from FDA on Initial Pediatric Study Plan for AP-SA02 for the Treatment of Complicated Staphylococcus aureus Bacteremia | ARMP Stock NewsStockTitan·Jul 12 at 10:00 PMARMP-10.73%
Armata Pharma amends 8-K to disclose director Daniel Gilmer committee assignmentPUBT·Jun 24 at 03:20 PMARMP-10.73%
Armata Pharmaceuticals receives additional USD 2.5 million DoD funding for AP-SA02 programPUBT·Jun 23 at 06:01 AMARMP-10.73%
